Slingshot members are tracking this event:

GlycoMimetics Set to Initiate Phase 1 Trials for GMI-1359 After Promising Data from Preclinical Trials

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details GlycoMimetics released preclinical trial data in December 2015 on GMI-1359 that aims to enhance the ability of chemotherapy to "target and improve survival from FLT3-ITD mutated acute myeloid leukemia (AML)".  Following this release, the Company expects to begin Phase 1 trials in 2H of 2016 following a filing for IND.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 06, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Gmi-1359, Phase 1 Clinical Study, Chemotherapy